Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.750 +0.020 (+0.73%)

Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

October 06, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗

September 18, 2025

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.

Via Benzinga

Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

September 05, 2025

Via Benzinga

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

September 02, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Earnings Scheduled For May 12, 2025 ↗

May 12, 2025

Via Benzinga

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

August 28, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Participate in Upcoming Investor Conferences

August 27, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Why Editas Medicine Stock Was Skyrocketing This Week ↗

August 15, 2025

The company's CEO made quite the encouraging statement regarding its immediate future.

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 13, 2025

Via Benzinga

Top movers in Wednesday's session ↗

August 13, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Wednesday's session: gap up and gap down stocks ↗

August 13, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

Editas Medicine Inc (NASDAQ:EDIT) Reports Mixed Q2 2025 Earnings: Revenue Beat but Wider Loss ↗

August 12, 2025

Editas Medicine posted Q2 2025 revenue of $3.58M, beating estimates, but EPS loss widened to -$0.63. Stock dipped 1.75% amid restructuring concerns. Pipeline progress includes IND filing plans for...

Via Chartmill

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

August 12, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Can This Beaten-Down Stock Bounce Back? ↗

August 12, 2025

This small-cap biotech is seeking to develop breakthrough therapies, but so far it's found little success.

Via The Motley Fool

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? ↗

June 28, 2025

Via The Motley Fool

Topics Workforce

2 Beaten-Down Stocks to Avoid ↗

June 27, 2025

Via The Motley Fool

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗

June 18, 2025

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Via Benzinga

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. ↗

June 17, 2025

Via The Motley Fool

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover ↗

June 17, 2025

The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.

Via Investor's Business Daily

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

June 12, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

1 Stock Down 97% That Could Double, According to Wall Street ↗

May 25, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 21, 2025

Via Benzinga

Editas Medicine: A Cautionary Tale for Investors ↗

May 15, 2025

Via The Motley Fool

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

May 14, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

May 14, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces First Quarter 2025 Results and Business Updates

May 12, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

May 12, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

May 05, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

April 28, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.